Back to News
Market Impact: 0.4
Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
Source: PR Newswire
Healthcare & BiotechCorporate Guidance & Outlook
Akeso announced positive overall-survival results from its randomized, double-blind, multicenter registrational Phase III HARMONi-2 (AK112-303) lung-cancer study at the 2026 World Conference on Lung Cancer. The positive Phase III survival data could support regulatory progress and strengthen the commercial outlook for Akeso's oncology pipeline, though the release excerpt provided no specific survival metrics or regulatory timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Labubu-maker Pop Mart's shares extend declines as third-quarter sales plunge
- Boeing shares slide on a disappointing cash flow update. Why this dip is buyable
- AI debt fears ease ahead of Oracle, Alphabet and Amazon updates. Here's what to watch.
- Airlines are trading nearly 23% higher ticket prices for emptier planes as jet fuel prices spike over 90% from the Iran War’s fuel squeeze
- Stifel’s surprise gaming pick leads a sector bracing for a choppy earnings season
- The big takeaways and big questions from Anthropic’s S-1